High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 3, 1998, Pages 525-533

  Mate, Timothy P ^a   Gottesman, James E ^a   Hatton, John ^a   Gribble, Michael ^a   Van Hollebeke, Lynn ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Cancer; High dose rate; Implant; Iridium; Prostate

Indexed keywords

BIOCHEMICAL MARKER; IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; ECHOGRAPHY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; URINARY TRACT DISEASE;

AGED; BRACHYTHERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE;

EID: 0031779940     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00097-2     Document Type: Article

References (25)

1. Whitmore W.F., Hilaris B., Grabstald H. Retropubic implantation of iodine-125 in the treatment of prostatic carcinoma. J. Urol. 108:1972;918-920.
2. Gottesman J., Tesh D., Weissman W. Failure of radioactive I-125 to control localized prostate cancer - a study of 41 patients. J. Urol. 146:1991;1317-1320.
3. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. I-125 Interstitial implantation in the definitive treatment of prostate cancer what have we learned 10 years later? Cancer. 63:1989;2415-2420.
4. Fuks Z., Leibel S.A., Wallner K.E. The effect of local control on metastatic dissemination in carcinoma of the prostate long-term results in patients treated with 125-I implantation . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;537-547.
5. Koprowski C.D., Berkenstock K.G., Borofski A.M. External beam irradiation versus 125 iodine implant in the definitive treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 21:1991;955-960.
6. Russel, K. J.; Blasko, J. C. Recent advances in interstitial brachytherapy for localized prostate cancer. In: Lange, P., ed. Problems in urology. Vol. 7. No. 2. Philadelphia: Lippincott, 1993:260-272.
7. Holm H.H., Juul N., Pedersen J.F. Transperineal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol. 130:1983;283-286.
8. Blasko J., Ragde H., Luse R., Sylvester J., Cavanaugh W., Grimm P. Should brachytherapy be considered a therapeutic option in localized prostate cancer. Urol. Clin. NA. 23:1996;633-650.
9. Mate, T.; Blasko, J.; Marshall, S.; Porter, B.; Schumaker, D. Computed tomography-assisted permanent prostate implant dosimetry. Proceedings of the Twelfth Annual Mid-Winter Meeting of the American. Endocurietherapy Society. 1989:14.
10. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma Correlation with histologic pattern and direction of spread . Am. J. Surg. Pathol. 12:1988;897-906.
11. Bertermann H., Brix F. Ultrasonically guided interstitial high dose rate brachytherapy with Ir-192 Technique and preliminary results in locally confined prostate cancer . Martinez A.A., Orton C.G., Mould R. Brachytherapy HDR and LDR. Remote afterloading state of art. 1990;281-303 Nucletron International B.V, Leerson, The Netherlands.
12. Mate T.P., Kovacs G., Martinez A. High dose rate brachytherapy of the prostate. Nag S. High dose rate brachytherapy A textbook . 1994;355-371 Futura Publishing Co, Armonk, NY.
13. Blasko J., Ragde H., Grimm P.D. Transperineal ultrasound-guided Implantation of the prostate Morbidity and complications . Scand. J. Urol. Nephrol. 137:(Suppl.):1991;113-118.
14. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int. J. Radiol. Oncol. Biol. Phys. 37:1997;565-569.
15. 125I prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 37:(3):1997;559-563.
16. D'Amico A.V., Whittington R., Kaplan I., Beard C., Jiroutek M.S., Malkowicz S.B., Wein A., Coleman C.N. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1053-1058.
17. Hanks G.E., Lee R.W., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., Movsas B., Schultheiss T.E. Conformal technique dose escalation for prostate cancer biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ ng/ml . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;861-868.
18. Kupelian P., Katcher J., Levin H., Zippe C., Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:(2):1996;249-260.
19. Kovacs G., Wirth B., Bertermann H., Galalae R., Kohr P., Wilhelm R., Kimmig B. Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients - An intermediate analysis after ten years experience. (Abstr.). Int. J. Radiat. Oncol. Biol. Phys. 36:(suppl. 1):1996;198.
20. Stromberg J., Martinez A., Horwitz E. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer superior prostate-specific antigen response compared with external beam treatment . Sci. Am. 3:1997;346-352.
21. Prestidge B.R., Kaplan I., Cox R.S., Bagshaw M.A. Predictors of survival after a positive post-irradiation prostate biopsy. Int. J. Radiol. Oncol. Biol. Phys. 28:1993;17-22.
22. Partin A.W., Kattan M.W., Subong E., Walsh P., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 277:1997;1445-1451.
23. Laverdiere J., Gomez J.L., Cusan L., Suburu E.R., Diamond P., Lemay M., Candas B., Fortin A., Labrie F. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;247-252.
24. Pilepich M.V., Krall J.M., Al-Serraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostate carcinoma A randomized comparative trial of the radiation therapy Oncology Group . Urology. 45:1995;616-623.
25. Kurhananewicz J., Vigneron D.B., Hriack H., Naryan P., Carroll P., Nelson S.J. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7 cm3) spatial resolution. Radiology. 198:1996;795-805.